BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Journal of the American College of Surgeons 2016;223:52-65. [DOI: 10.1016/j.jamcollsurg.2016.02.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Crippa S, Piccioli A, Guarneri G, Longo E, Falconi M. Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm? Endosc Ultrasound 2017;6:S62-5. [PMID: 29387691 DOI: 10.4103/eus.eus_61_17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hoefer RA, Obiora C, Azab B, Harden EA, Kessler JF. Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report. Int J Surg Case Rep 2021;83:106047. [PMID: 34091215 DOI: 10.1016/j.ijscr.2021.106047] [Reference Citation Analysis]
3 Kim YJ, Koh HK, Chie EK, Oh DY, Bang YJ, Nam EM, Kim K. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. Int J Clin Oncol 2017;22:1069-75. [PMID: 28477059 DOI: 10.1007/s10147-017-1129-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Petrelli F, Inno A, Barni S, Ghidini A, Labianca R, Falconi M, Reni M, Cascinu S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) and San Raffaele Hospital. Borderline resectable pancreatic cancer: More than an anatomical concept. Dig Liver Dis 2017;49:223-6. [PMID: 27931968 DOI: 10.1016/j.dld.2016.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
5 Bergquist JR, Shubert CR, Storlie CB, Habermann EB, Truty MJ. Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. JCO 2017;35:1622-3. [DOI: 10.1200/jco.2016.71.2315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xu WL, Wang J, Lyu SC, Zhou L, He Q, Lang R. Ratio of CA19-9 level to total bilirubin as a novel prognostic indicator in patients with pancreatic head carcinoma following curative resection. Gland Surg 2021;10:980-91. [PMID: 33842242 DOI: 10.21037/gs-20-720] [Reference Citation Analysis]
7 Yonkus JA, Alva-Ruiz R, Abdelrahman AM, Leiting JL, Schneider AR, Grotz TE, Cleary SP, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Truty MJ. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinical Trial. J Am Coll Surg 2021;233:73-80.e1. [PMID: 34022414 DOI: 10.1016/j.jamcollsurg.2021.05.009] [Reference Citation Analysis]
8 Zhang S, Huang X, Tian Y, Aimaiti S, Zhang J, Zhao J, Chen Y, Wang C. Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China. PeerJ 2018;6:e4893. [PMID: 29868287 DOI: 10.7717/peerj.4893] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Rodrigues V, Dopazo C, Pando E, Blanco L, Caralt M, Gómez-Gavara C, Bilbao I, Salcedo MT, Balsells J, Charco R. Is the involvement of the hepatic artery lymph node a poor prognostic factor in pancreatic adenocarcinoma? Cir Esp (Engl Ed) 2020;98:204-11. [PMID: 31839175 DOI: 10.1016/j.ciresp.2019.09.015] [Reference Citation Analysis]
10 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
11 de Geus SW, Eskander MF, Bliss LA, Kasumova GG, Ng SC, Callery MP, Tseng JF. Neoadjuvant therapy vs upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery. 2017;161:592-601. [PMID: 28341441 DOI: 10.1016/j.surg.2016.08.040] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
12 Fang T, Wang H, Wang Y, Lin X, Cui Y, Wang Z. Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma. Dis Markers. 2019;2019:6016931. [PMID: 30863466 DOI: 10.1155/2019/6016931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Coppola A, La Vaccara V, Fiore M, Farolfi T, Ramella S, Angeletti S, Coppola R, Caputo D. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Front Oncol 2021;11:690580. [PMID: 34123859 DOI: 10.3389/fonc.2021.690580] [Reference Citation Analysis]
15 Lu H, Niu F, Liu F, Gao J, Sun Y, Zhao X. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med 2017;6:1181-91. [PMID: 28440066 DOI: 10.1002/cam4.1064] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
16 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
17 Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971-976. [PMID: 30131287 DOI: 10.1016/j.pan.2018.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
18 Yang Z, LaRiviere MJ, Ko J, Till JE, Christensen T, Yee SS, Black TA, Tien K, Lin A, Shen H, Bhagwat N, Herman D, Adallah A, O'Hara MH, Vollmer CM, Katona BW, Stanger BZ, Issadore D, Carpenter EL. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3248-58. [PMID: 32299821 DOI: 10.1158/1078-0432.CCR-19-3313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Bonds M, Rocha FG. Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E1205. [PMID: 31409042 DOI: 10.3390/jcm8081205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
20 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
22 Portuondo JI, Massarweh NN, Zhang Q, Chai CY, Tran Cao HS. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Surgery 2019;165:1144-50. [PMID: 30745009 DOI: 10.1016/j.surg.2018.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, Shin D, Kim H, Sung M, Ryu Y, Kim SC. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(11): 1423-1435 [DOI: 10.4240/wjgs.v13.i11.1423] [Reference Citation Analysis]
24 Jin K, Lan H, Chen X, Wang S, Ying X, Lin Y, Mou X. Recent advances in carbohydrate-based cancer vaccines. Biotechnol Lett 2019;41:641-50. [DOI: 10.1007/s10529-019-02675-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
25 Bowman AW, Bolan CW. MRI evaluation of pancreatic ductal adenocarcinoma: diagnosis, mimics, and staging. Abdom Radiol 2019;44:936-49. [DOI: 10.1007/s00261-018-1686-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pergolini I, Crippa S, Salgarello M, Belfiori G, Partelli S, Ruffo G, Pucci A, Zamboni G, Falconi M. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. Digestive and Liver Disease 2018;50:84-90. [DOI: 10.1016/j.dld.2017.09.122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Barreto SG. Pancreatic Cancer. In: Barreto SG, Windsor JA, editors. Surgical Diseases of the Pancreas and Biliary Tree. Singapore: Springer; 2018. pp. 427-69. [DOI: 10.1007/978-981-10-8755-4_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Lyu SC, Wang J, Huang M, Wang HX, Zhou L, He Q, Lang R. CA19-9 Level to Serum γ-Glutamyltransferase as a Potential Prognostic Biomarker in Patients with Pancreatic Head Carcinoma. Cancer Manag Res 2021;13:4887-98. [PMID: 34188542 DOI: 10.2147/CMAR.S313517] [Reference Citation Analysis]
29 Jiang T, Lyu SC, Zhou L, Wang J, Li H, He Q, Lang R. Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma. World J Gastrointest Surg 2021; 13(9): 1025-1038 [PMID: 34621478 DOI: 10.4240/wjgs.v13.i9.1025] [Reference Citation Analysis]
30 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo 2018;32:1533-40. [PMID: 30348713 DOI: 10.21873/invivo.11411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
31 Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. J Gastrointest Cancer 2018;49:481-6. [PMID: 28924968 DOI: 10.1007/s12029-017-0007-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
32 Palumbo D, Mori M, Prato F, Crippa S, Belfiori G, Reni M, Mushtaq J, Aleotti F, Guazzarotti G, Cao R, Steidler S, Tamburrino D, Spezi E, Del Vecchio A, Cascinu S, Falconi M, Fiorino C, De Cobelli F. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers (Basel) 2021;13:4938. [PMID: 34638421 DOI: 10.3390/cancers13194938] [Reference Citation Analysis]
33 Guarneri G, Gasparini G, Crippa S, Andreasi V, Falconi M. Diagnostic strategy with a solid pancreatic mass. La Presse Médicale 2019;48:e125-45. [DOI: 10.1016/j.lpm.2019.02.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
34 Santucci N, Facy O, Ortega-Deballon P, Lequeu JB, Rat P, Rat P. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology 2018;18:666-70. [PMID: 30153902 DOI: 10.1016/j.pan.2018.07.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
36 Abou-khalil J, Rocha FG. Surgical strategies and novel therapies for locally advanced pancreatic cancer. J Surg Oncol 2017;116:16-24. [DOI: 10.1002/jso.24654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
37 Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019;166:277-285. [PMID: 31272811 DOI: 10.1016/j.surg.2019.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
38 Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273:341-349. [PMID: 30946090 DOI: 10.1097/sla.0000000000003284] [Cited by in Crossref: 77] [Cited by in F6Publishing: 30] [Article Influence: 77.0] [Reference Citation Analysis]
39 Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, Borad M, Cleary SP, Truty MJ, Mahipal A. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol 2020;46:789-95. [PMID: 31954549 DOI: 10.1016/j.ejso.2020.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Uwagawa T, Sakamoto T, Yasuda J, Shiozaki H, Furukawa K, Onda S, Gocho T, Shiba H, Yanaga K. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas 2021;50:313-6. [PMID: 33835961 DOI: 10.1097/MPA.0000000000001767] [Reference Citation Analysis]
41 Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Reference Citation Analysis]
42 Kang CM. What Is the Next in Developing Model to Predict Survival Outcomes of Resected Pancreatic Cancer? Gut Liver 2021;15:797-8. [PMID: 34782489 DOI: 10.5009/gnl210503] [Reference Citation Analysis]
43 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
44 Lyu S, Wang F, Ren Z, He Q. Correlation analysis of CA19-9/Glutamyltransferase ratio and long-term survival for patients with pancreatic head cancer under different bilirubin levels. Asian J Surg 2021;44:765-6. [PMID: 33762143 DOI: 10.1016/j.asjsur.2021.02.027] [Reference Citation Analysis]
45 Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery 2017;162:104-11. [PMID: 28238344 DOI: 10.1016/j.surg.2016.12.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
46 Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 2018;9:996-1004. [PMID: 30603118 DOI: 10.21037/jgo.2018.05.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 Gao Z, Jiang W, Zhang S, Li P. The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma. Anal Cell Pathol (Amst) 2019;2019:9419072. [PMID: 31583198 DOI: 10.1155/2019/9419072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
49 Garnier J, Robin F, Ewald J, Marchese U, Bergeat D, Boudjema K, Delpero JR, Sulpice L, Turrini O. Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery? Ann Surg Oncol 2021;28:4625-34. [PMID: 33462718 DOI: 10.1245/s10434-020-09520-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book 2017. [DOI: 10.1200/edbk_175222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
51 Rose JB, Edwards AM, Rocha FG, Clark C, Alseidi AA, Biehl TR, Lin BS, Picozzi VJ, Helton WS. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Oncologist. 2020;25:859-866. [PMID: 32277842 DOI: 10.1634/theoncologist.2019-0878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
52 Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G, Chai C, Katz MH, Fisher WE, Massarweh NN. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery 2017;162:557-67. [DOI: 10.1016/j.surg.2017.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
53 Schenk J, Nagy G, Pohl NL, Leghissa A, Smuts J, Schug KA. Identification and deconvolution of carbohydrates with gas chromatography-vacuum ultraviolet spectroscopy. Journal of Chromatography A 2017;1513:210-21. [DOI: 10.1016/j.chroma.2017.07.052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
54 de Jesus VHF, da Costa Junior WL, de Miranda Marques TMD, Diniz AL, de Castro Ribeiro HS, de Godoy AL, de Farias IC, Coimbra FJF. Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single-center experience from a tertiary hospital in Brazil. J Surg Oncol 2018;117:819-28. [PMID: 29509968 DOI: 10.1002/jso.25024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Recio-Boiles A, Nallagangula A, Veeravelli S, Vondrak J, Saboda K, Roe D, Elquza E, McBride A, Babiker HM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2019;2. [PMID: 31360919 DOI: 10.21037/apc.2019.06.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, Smoot RL, Kendrick ML, Farnell MB, Roberts LR. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. J Surg Oncol. 2016;114:475-482. [PMID: 27439662 DOI: 10.1002/jso.24381] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
57 Ballard DD, Rahman S, Ginnebaugh B, Khan A, Dua KS. Safety and efficacy of self-expanding metal stents for biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer. Endosc Int Open 2018;6:E714-21. [PMID: 29868636 DOI: 10.1055/a-0599-6190] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Truty MJ, Colglazier JJ, Mendes BC, Nagorney DM, Bower TC, Smoot RL, Demartino RR, Cleary SP, Oderich GS, Kendrick ML. En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Journal of the American College of Surgeons 2020;231:8-29. [DOI: 10.1016/j.jamcollsurg.2020.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
59 de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. J Gastrointest Surg 2018;22:214-25. [PMID: 29235000 DOI: 10.1007/s11605-017-3541-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
60 de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. Biomark Insights 2017;12:1177271917715443. [PMID: 28690396 DOI: 10.1177/1177271917715443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
61 Miccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clin Transl Radiat Oncol 2021;27:15-23. [PMID: 33392398 DOI: 10.1016/j.ctro.2020.12.003] [Reference Citation Analysis]
62 Mirkin KA, Hollenbeak CS, Wong J. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. J Gastrointest Oncol 2017;8:778-88. [PMID: 29184681 DOI: 10.21037/jgo.2017.07.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
63 Bergquist JR, Thiels CA, Shubert CR, Ivanics T, Habermann EB, Vege SS, Grotz TE, Cleary SP, Smoot RL, Kendrick ML, Nagorney DM, Truty MJ. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Cancer Med 2021. [PMID: 34289264 DOI: 10.1002/cam4.4144] [Reference Citation Analysis]
64 Yun G, Kim YH, Lee YJ, Kim B, Hwang JH, Choi DJ. Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection. Sci Rep. 2018;8:7226. [PMID: 29740111 DOI: 10.1038/s41598-018-25627-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
65 Fitzgerald TL, Hunter L, Mosquera C, Jindal C, Biswas T, Zervos E, Efird JT. A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. HPB (Oxford) 2019;21:204-11. [PMID: 30087052 DOI: 10.1016/j.hpb.2018.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Chang C, Chen P, Wang S, Hsu S, Hsu W, Tsai C, Wadekar PV, Puttaswamy S, Cheng K, Hsieh S, Wang HJ, Kuo K, Sun Y, Tu L. Fast detection of tumor marker CA 19-9 using AlGaN/GaN high electron mobility transistors. Sensors and Actuators B: Chemical 2018;267:191-7. [DOI: 10.1016/j.snb.2018.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
67 Caputo D, Papi M, Coppola R, Palchetti S, Digiacomo L, Caracciolo G, Pozzi D. A protein corona-enabled blood test for early cancer detection. Nanoscale 2017;9:349-54. [DOI: 10.1039/c6nr05609a] [Cited by in Crossref: 56] [Cited by in F6Publishing: 15] [Article Influence: 11.2] [Reference Citation Analysis]
68 Schiergens TS, Renz BW, Reu S, Neumann J, Al-sayegh R, Nieß H, Ilmer M, Kruger S, Boeck S, Heinemann V, Werner J, Kleespies A. Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. J Gastrointest Surg 2017;21:1775-83. [DOI: 10.1007/s11605-017-3489-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Armstrong EA, Beal EW, Chakedis J, Paredes AZ, Moris D, Pawlik TM, Schmidt CR, Dillhoff ME. Exosomes in Pancreatic Cancer: from Early Detection to Treatment. J Gastrointest Surg. 2018;22:737-750. [PMID: 29423813 DOI: 10.1007/s11605-018-3693-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
71 Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol 2021;11:651119. [PMID: 34046346 DOI: 10.3389/fonc.2021.651119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Al Abbas AI, Zenati M, Reiser CJ, Hamad A, Jung JP, Zureikat AH, Zeh HJ 3rd, Hogg ME. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2020;27:2007-2014. [PMID: 31898105 DOI: 10.1245/s10434-019-08156-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
73 Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T, Fujita H, Hakamada K. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. Ann Surg Oncol 2021. [PMID: 34608555 DOI: 10.1245/s10434-021-10866-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Abe T, Amano H, Kobayashi T, Hattori M, Hanada K, Nakahara M, Ohdan H, Noriyuki T. Efficacy of the physiobiological parameter-based grading system for predicting the long-term prognosis after curative surgery for resectable pancreatic cancer. Eur J Surg Oncol 2021;47:613-9. [PMID: 32978015 DOI: 10.1016/j.ejso.2020.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Ikoma N, Katz MHG. Improving Outcomes After Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): As Always, it is All About Patient Selection. Ann Surg Oncol 2019;26:703-4. [PMID: 30539493 DOI: 10.1245/s10434-018-07104-x] [Reference Citation Analysis]
76 Jo JH, Kim SA, Lee JH, Park YR, Kim C, Park SB, Jung DE, Lee HS, Chung MJ, Song SY. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:1241. [PMID: 34794402 DOI: 10.1186/s12885-021-08898-y] [Reference Citation Analysis]
77 Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr Med Chem. 2019;26:7196-7211. [PMID: 29651946 DOI: 10.2174/0929867325666180413101722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
78 Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. J Surg Oncol 2020;122:1074-83. [PMID: 32673436 DOI: 10.1002/jso.26103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]